The results of progression-free survival in CRC were also worse than those observed in NSCLC.35 Consistent with this, Amodio et al36 observed that KRASG12C inhibitors produce less profound and more transient inhibition of KRAS downstream signaling in CRC compared with NSCLC models. This evidence concerns the gene KRAS and colorectal carcinoma.